Trial reportBMC pediatrics2026
Mortality impact of an increased blood glucose cut-off level for hypoglycaemia treatment in severely sick children aged 5 to 12 years in Malawi - an exploratory randomised controlled study.
Trial report in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02989675 (SugarFACT - Sugar Requirements For African Children Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SugarFACT - Sugar Requirements For African Children Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow blood glucose concentration is a well-recognized risk factor for mortality in children admitted to hospitals in low-income settings. Current WHO guidelines define hypoglycaemia as a blood glucose level below 2.5 mmol/L; however, this threshold has been questioned. In a trial conducted in Malawian hospitals, increasing the treatment threshold to 5.0 mmol/L did not reduce in-hospital mortality among children aged 1 month to 5 years. The physiological response to low glucose and dextrose treatment in older children may differ yet remains understudied. This exploratory analysis was conducted to assess potential effects of dextrose treatment in severely ill children aged 5–12 years with blood glucose concentrations between 2.5 and 5.0 mmol/L.
methodsThe study is an exploratory extension of a pragmatic randomised controlled trial where all eligible children were randomised to receive either a 5 ml/kg intravenous bolus followed by maintenance infusion of 10% dextrose (intervention group) or observation and standard care (control group). The primary outcome was in-hospital mortality; the secondary outcome was 24-hour mortality.
resultsSeventy-two children were enrolled with 36 allocated to each group. In-hospital mortality was 8% (3/36) in the intervention group and 19% (7/36) in the control group with an odds ratio (OR) for mortality of 0.8 (95% CI 0.46–2.25). The mortality after 24 h was 3% (1/36) in the intervention group and 8% (3/36) in the control group, with an OR of 0.4 (95% CI. 0.06–2.90). Adverse events occurred in 19% (7/36) in the intervention group and 39% (14/36) in the control group.
conclusionThis exploratory analysis suggests a potential reduction in mortality when intravenous dextrose treatment is administered to severely ill children aged 5–12 years who present to hospital with a low blood glucose. However, as the parent trial was powered for children less than 5 years the sample size for this older age group was insufficient to draw definitive conclusions. Larger, age-specific studies are warranted to determine the potential benefit of dextrose treatment in this population.
trial registrationThe study is registered with ClinicalTrials.gov, NCT02989675 on 7th December 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.